Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening

Resnick, Efrat, Bradley, Anthony, Gan, Jinrui, Douangamath, Alice, Krojer, Tobias, Sethi, Ritika, Geurink, Paul P., Aimon, Anthony, Amitai, Gabriel, Bellini, Dom, Bennett, James, Fairhead, Michael, Fedorov, Oleg, Gabizon, Ronen, Gan, Jin, Guo, Jingxu, Plotnikov, Alexander, Reznik, Nava, Ruda, Gian Filippo, Díaz-Sáez, Laura, Straub, Verena M., Szommer, Tamas, Velupillai, Srikannathasan, Zaidman, Daniel, Zhang, Yanling, Coker, Alun R., Dowson, Christopher G., Barr, Haim M., Wang, Chu, Huber, Kilian V.M., Brennan, Paul E., Ovaa, Huib, von Delft, Frank, London, Nir·2019·Journal of the American Chemical Society
DOI 10.1021/jacs.9b02822

Cited by (349)

Items 101–200 of 349

  1. Screening for Inhibitors of Main Protease in SARS-CoV-2: In Silico and In Vitro Approach Avoiding Peptidyl Secondary Amides
    Kazuki Z. Yamamoto, Nobuaki Yasuo, Masakazu Sekijima · 2022 · Journal of Chemical Information and Modeling
  2. Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds
    Matic Proj, Damijan Knez, Izidor Sosič, Stanislav Gobec · 2022 · Drug Discovery Today
  3. Innovative design and potential applications of covalent strategy in drug discovery
    Tianyong Tang, Jiaxiang Luo, Dan Zhang, Yang Lü, Wen Liao, Jifa Zhang · 2024 · European Journal of Medicinal Chemistry
  4. Assessment of Tractable Cysteines for Covalent Targeting by Screening Covalent Fragments
    László Petri, Péter Ábrányi‐Balogh, Tı́mea Imre, Gyula Pálfy, András Perczel, Damijan Knez, Martina Hrast, Martina Gobec, Izidor Sosič, Kinga Nyíri et al. · 2020 · ChemBioChem
  5. Design, synthesis and bioevaluation of 1,2,4-thiadiazolidine-3,5-dione derivatives as potential GSK-3β inhibitors for the treatment of Alzheimer's disease
    Dong, Yongxi, Lu, Jun, Zhang, Shanhui, Chen, Lina, Wen, Jinlan, Wang, Fang, Mao, Yongqing, Li, Lei, Zhang, Jiquan, Liao, Shanggao et al. · 2023 · Bioorganic Chemistry
  6. Expedited SARS‐CoV‐2 Main Protease Inhibitor Discovery through Modular ‘Direct‐to‐Biology’ Screening
    Harry Wilders, George S. Biggs, Sam M. Rowe, Emma E. Cawood, Ioannis G. Riziotis, Alan R. Rendina, Emma K. Grant, Jonathan Pettinger, David J. Fallon, Mark J. Skehel et al. · 2024 · Angewandte Chemie International Edition
  7. Electrophilic Natural Products as Drug Discovery Tools
    Paul Gehrtz, Nir London · 2021 · Trends in Pharmacological Sciences
  8. Covalent flexible peptide docking in Rosetta
    Barr Tivon, Ronen Gabizon, Bente A. Somsen, Peter J. Cossar, Christian Ottmann, Nir London · 2021 · Chemical Science
  9. Advances in reversible covalent kinase inhibitors
    Zheng Zhao, Philip E. Bourne · 2024 · Medicinal Research Reviews
  10. Delineating cysteine-reactive compound modulation of cellular proteostasis processes
    Ashley R. Julio, Flowreen Shikwana, Cindy C. Truong, Nikolas R. Burton, Emil R. Dominguez, Alexandra C. Turmon, Jian Xin Cao, Keriann M. Backus · 2024 · Nature Chemical Biology
  11. Covalent inhibitors of bacterial peptidoglycan biosynthesis enzyme MurA with chloroacetamide warhead
    Katarina Grabrijan, Martina Hrast, Matic Proj, Ana Dolšak, Irena Zdovc, Tı́mea Imre, László Petri, Péter Ábrányi‐Balogh, György Miklós Keserű, Stanislav Gobec · 2022 · European Journal of Medicinal Chemistry
  12. Discovery and optimization of covalent Bcl-xL antagonists
    Herschel Mukherjee, Nancy Su, Matthew A. Belmonte, David Hargreaves, Joe Sahil Patel, Sharon Tentarelli, Brian M. Aquila, Neil P. Grimster · 2019 · Bioorganic & Medicinal Chemistry Letters
  13. Demonstration of the utility of DOS-derived fragment libraries for rapid hit derivatisation in a multidirectional fashion
    Sarah L. Kidd, Elaine Fowler, Till Reinhardt, Thomas Compton, Natalia Mateu, Hector Newman, Dom Bellini, Romain Talon, Joseph McLoughlin, Tobias J. Krojer et al. · 2020 · Chemical Science
  14. Inverse Drug Discovery identifies weak electrophiles affording protein conjugates
    Gabriel M. Kline, Karina Nugroho, Jeffery W. Kelly · 2022 · Current Opinion in Chemical Biology
  15. Technologies for Direct Detection of Covalent Protein–Drug Adducts
    Elma Mons, Robbert Q. Kim, Monique P. C. Mulder · 2023 · Pharmaceuticals
  16. Solid-Phase Compatible Silane-Based Cleavable Linker Enables Custom Isobaric Quantitative Chemoproteomics
    Burton, Nikolas R., Polasky, Daniel A., Shikwana, Flowreen, Ofori, Samuel, Yan, Tianyang, Geiszler, Daniel J., Veiga Leprevost, Felipe da, Nesvizhskii, Alexey I., Backus, Keriann M. · 2023 · Journal of the American Chemical Society
  17. An mRNA Display Approach for Covalent Targeting of a Staphylococcus aureus Virulence Factor
    Sijie Wang, Emily C. Woods, Jeyun Jo, Jiyun Zhu, Althea Hansel-Harris, Matthew Holcomb, Manuel A. Llanos, Nichole J. Pedowitz, Tulsi Upadhyay, John M. Bennett et al. · 2025 · Journal of the American Chemical Society
  18. Many small steps towards a COVID-19 drug
    Daniel A. Erlanson · 2020 · Nature Communications
  19. A loss‐of‐function cysteine mutant in fibulin‐3 (EFEMP1) forms aberrant extracellular disulfide‐linked homodimers and alters extracellular matrix composition
    DaNae R. Woodard, Steffi Daniel, Emi Nakahara, Ali Abbas, Sophia M. DiCesare, Gracen E. Collier, John D. Hulleman · 2022 · Human Mutation
  20. Targeting the ubiquitin system by fragment-based drug discovery
    Cassandra R. Kennedy, Katherine A. McPhie, Katrin Rittinger · 2022 · Frontiers in Molecular Biosciences
  21. Fragmenstein: predicting protein–ligand structures of compounds derived from known crystallographic fragment hits using a strict conserved-binding–based methodology
    Matteo Paolo Ferla, Rubén Sánchez-García, R. Skyner, Stefan Gahbauer, Jenny C. Taylor, F. von Delft, Brian D. Marsden, Charlotte Mary Deane · 2025 · Journal of Cheminformatics
  22. Opportunities and challenges for the development of covalent chemical immunomodulators
    Keriann M. Backus, Jian Xin Cao, Sean M. Maddox · 2019 · Bioorganic & Medicinal Chemistry
  23. N -Acylamino Saccharin as an Emerging Cysteine-Directed Covalent Warhead and Its Application in the Identification of Novel FBPase Inhibitors toward Glucose Reduction
    Wuqiang Wen, Hongxuan Cao, Yixiang Xu, Yanliang Ren, Li Rao, Xubo Shao, Han Chen, Lixia Wu, Jiaqi Liu, Su Chen et al. · 2022 · Journal of Medicinal Chemistry
  24. Fragment-based screening: A new paradigm for ligand and target discovery
    Sinéad Knight, Davide Gianni, Adam Hendricks · 2022 · SLAS DISCOVERY
  25. HCovDock: an efficient docking method for modeling covalent protein–ligand interactions
    Qilong Wu, Sheng‐You Huang · 2022 · Briefings in Bioinformatics
  26. Reactive fragments targeting carboxylate residues employing direct to biology, high-throughput chemistry
    Ross P. Thomas, Emma K. Grant, Eleanor R. Dickinson, Francesca Zappacosta, Lee J. Edwards, Michael M. Hann, David House, Nicholas C. O. Tomkinson, Jacob T. Bush · 2023 · RSC Medicinal Chemistry
  27. Evaluation of a Covalent Library of Diverse Warheads (CovLib) Binding to JNK3, USP7, or p53
    Theresa Klett, Martin Schwer, Larissa N. Ernst, Marc U. Engelhardt, Simon Jaag, Benedikt Masberg, Cornelius Knappe, Michael Lämmerhofer, Matthias Gehringer, Frank M. Boeckler · 2024 · Drug Design Development and Therapy
  28. High-Throughput Covalent Modifier Screening with Acoustic Ejection Mass Spectrometry
    Xiujuan Wen, Chang Liu, Kiersten Tovar, Patrick Curran, Matthew P. Richards, Sony Agrawal, RICHARD M. JOHNSTONE, Ryan E. Loy, Joey L. Methot, My Sam Mansueto et al. · 2024 · Journal of the American Chemical Society
  29. Multiparameter Kinetic Analysis for Covalent Fragment Optimization by Using Quantitative Irreversible Tethering (qIT)
    Gregory B. Craven, Dominic P. Affron, Teresa Kösel, Tsz Lam Wong, Zoë Jukes, Chun‐Ting Liu, Rhodri M. L. Morgan, Alan Armstrong, David J. Mann · 2020 · ChemBioChem
  30. Discovery of Non-Cysteine-Targeting Covalent Inhibitors by Activity-Based Proteomic Screening with a Cysteine-Reactive Probe
    Ye‐Jin Jung, Naotaka Noda, Junichiro Takaya, Masahiro Abo, Kohei Toh, Ken Tajiri, Changyi Cui, Lu Zhou, Shin‐ichi Sato, Motonari Uesugi · 2022 · ACS Chemical Biology
  31. Selective Covalent Targeting of Pyruvate Kinase M2 Using Arsenous Warheads
    Wang, Jingyao, Zhou, Shaoqing, Cheng, Yan, Cheng, Lin, Qin, Ying, Zhang, Zhenfeng, Bi, Aiwei, Xiang, Huaijiang, He, Xinheng, Tian, Xiaoxu et al. · 2023 · Journal of Medicinal Chemistry
  32. Tunable Heteroaromatic Nitriles for Selective Bioorthogonal Click Reaction with Cysteine
    Matic Proj, Nika Strašek, Stane Pajk, Damijan Knez, Izidor Sosič · 2023 · Bioconjugate Chemistry
  33. Fragment-based drug discovery campaigns guided by native mass spectrometry
    Louise M. Sternicki, Sally‐Ann Poulsen · 2024 · RSC Medicinal Chemistry
  34. Diffusion Limit and the Reactivity/Affinity Conundrum: Implications for Optimization and Hit Finding for Irreversible Modulators
    Bharath Srinivasan · 2025 · Journal of Medicinal Chemistry
  35. Genetic validation of Aspergillus fumigatus phosphoglucomutase as a viable therapeutic target in invasive aspergillosis
    Kaizhou Yan, Mathew Stanley, Bartosz Kowalski, Olawale G. Raimi, Andrew T. Ferenbach, Pingzhen Wei, Wenxia Fang, Daan M. F. van Aalten · 2022 · Journal of Biological Chemistry
  36. Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
    Qiong Li, Li Zhou, Siyuan Qin, Zhao Huang, Bowen Li, Bowen Li, Mei Yang, Edouard Collins Nice, Huili Zhu, Canhua Huang · 2023 · European Journal of Medicinal Chemistry
  37. Functionalizing tandem mass tags for streamlining click-based quantitative chemoproteomics
    Nikolas R. Burton, Keriann M. Backus · 2024 · Communications Chemistry
  38. Discovery of RNA-Reactive Small Molecules Guides the Design of Electrophilic Modules for RNA-Specific Covalent Binders
    Noah A. Springer, Patrick R. A. Zanon, Amirhossein Taghavi, Kisu Sung, Matthew David Disney · 2025 · Journal of the American Chemical Society
  39. Discovery of selective fragment-sized immunoproteasome inhibitors
    Levente Kollár, Martina Gobec, Bence Szilágyi, Matic Proj, Damijan Knez, Péter Ábrányi‐Balogh, László Petri, Tı́mea Imre, Dávid Bajusz, György G. Ferenczy et al. · 2021 · European Journal of Medicinal Chemistry
  40. The Current Toolbox for Covalent Inhibitors: From Hit Identification to Drug Discovery
    Mengke You, Hong Liu, Chunpu Li · 2025 · JACS Au
  41. Comparative reactivity profiling of cysteine-specific probes by chemoproteomics
    Fan Yang, Nan Chen, Fengzhang Wang, Guogeng Jia, Chu Wang · 2022 · Current Research in Chemical Biology
  42. N‐Cyanopiperazines as Specific Covalent Inhibitors of the Deubiquitinating Enzyme UCHL1
    Mirko Schmidt, Christian Grethe, Sarah Recknagel, Gian‐Marvin Kipka, Nikolas Klink, Malte Gersch · 2024 · Angewandte Chemie International Edition
  43. SuFEx Chemistry Enables Covalent Assembly of a 280-kDa 18-Subunit Pore-Forming Complex
    Lee Schnaider, Sophia K. Tan, Pratik Raj Singh, Floriana Capuano, Alistair J. Scott, Richard G. Hambley, Lei Lü, Hyunjun Yang, Elizabeth Jayne Wallace, Hyunil Jo et al. · 2024 · Journal of the American Chemical Society
  44. Kinetic mechanisms of covalent inhibition
    Claire L. McWhirter · 2021 · Annual reports in medicinal chemistry
  45. Development of Ubiquitin Variants with Selectivity for Ubiquitin C‑Terminal Hydrolase Deubiquitinases
    Chad S. Hewitt, Aaron D. Krabill, Chittaranjan Das, Daniel Patrick Flaherty · 2020 · Biochemistry
  46. Enantioselective OTUD7B fragment discovery through chemoproteomics screening and high-throughput optimisation
    Aini Vuorinen, Cassandra R. Kennedy, Katherine A. McPhie, William J. McCarthy, Jonathan Pettinger, Mark J. Skehel, David House, Jacob T. Bush, Katrin Rittinger · 2025 · Communications Chemistry
  47. FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms
    Mahmoud S. Ahmed, Ayman Farag, Ian N. Boys, Ping Wang, Ivan Menendez-Montes, Ngoc Uyen Nhi Nguyen, Jennifer L. Eitson, Maikke B. Ohlson, Wenchun Fan, Matthew B. McDougal et al. · 2023 · Biomedicine & Pharmacotherapy
  48. Design of a Lead-Like Cysteine-Targeting Covalent Library and the Identification of Hits to Cys55 of Bfl-1
    Simon C. C. Lucas, Alexander G. Milbradt, J. Henry Blackwell, Silvia Bonomo, Andrew Brierley, Doyle J. Cassar, Jared Freeman, Thomas E. Hadfield, Lucas A. Morrill, Rick Riemens et al. · 2024 · Journal of Medicinal Chemistry
  49. Irreversible inhibition of BoNT/A protease: proximity-driven reactivity contingent upon a bifunctional approach
    Lewis D. Turner, Alexander L. Nielsen, Lucy Q. Lin, Sabine Pellett, Takashi Sugane, Margaret E. Olson, Eric Arthur Johnson, Kim D. Janda · 2021 · RSC Medicinal Chemistry
  50. Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3Kδ
    Julie C. L. Fournier, John P. Evans, Francesca Zappacosta, Daniel A. Thomas, Vipulkumar K. Patel, Gemma V. White, Sébastien Campos, Nicholas C. O. Tomkinson · 2021 · ACS Chemical Biology
  51. Targeting the Ubiquitylation and ISGylation Machinery for the Treatment of COVID-19
    George Vere, Md Rashadul Alam, Sam Farrar, Rachel Kealy, Benedikt Mathias Kessler, Darragh Patrick O'Brien, Adán Pinto-Fernández · 2022 · Biomolecules
  52. The war on hTG2: warhead optimization in small molecule human tissue transglutaminase inhibitors
    Lavleen K. Mader, Sarah K. I. Watt, Harish Iyer, Linh Nhat Nguyen, Harpreet Kaur, Jeffrey W. Keillor · 2022 · RSC Medicinal Chemistry
  53. The right tools for the job: the central role for next generation chemical probes and chemistry-based target deconvolution methods in phenotypic drug discovery
    Manuela Jörg, Katrina S. Madden · 2021 · RSC Medicinal Chemistry
  54. Covalent Fragment Screening and Optimization Identifies the Chloroacetohydrazide Scaffold as Inhibitors for Ubiquitin C-terminal Hydrolase L1
    Ryan D. Imhoff, Rishi S. Patel, Muhammad Hassan Safdar, Hannah B. L. Jones, Adán Pinto-Fernández, Iolanda Vendrell, Hao Chen, Christine S. Muli, Aaron D. Krabill, Benedikt Mathias Kessler et al. · 2024 · Journal of Medicinal Chemistry
  55. Warheads for designing covalent inhibitors and chemical probes
    Péter Ábrányi‐Balogh, György Miklós Keserű · 2021 · Elsevier eBooks
  56. Optimization and Anti-Cancer Properties of Fluoromethylketones as Covalent Inhibitors for Ubiquitin C-Terminal Hydrolase L1
    Aaron D. Krabill, Hao Chen, Sajjad Hussain, Chad S. Hewitt, Ryan D. Imhoff, Christine S. Muli, Chittaranjan Das, Paul J. Galardy, Michael K. Wendt, Daniel Patrick Flaherty · 2021 · Molecules
  57. Forward Chemical Genetic Screen for Oxygen‐Dependent Cytotoxins Uncovers New Covalent Fragments that Target GPX4
    Marie B. Cordon, Kristian M. Jacobsen, Cecilie S. Nielsen, Per Hjerrild, Thomas Bjørnskov Poulsen · 2021 · ChemBioChem
  58. A chemoproteomic platform for selective deubiquitinase inhibitor discovery
    Rosa Cookson, Aini Vuorinen, Jonathan Pettinger, Cassandra R. Kennedy, Joanna M Kirkpatrick, Rachel E. Heap, Andrew Powell, Ambrosius P. Snijders, Mark J. Skehel, David House et al. · 2023 · Cell Reports Physical Science
  59. Binding‐Site Purification of Actives (B‐SPA) Enables Efficient Large‐Scale Progression of Fragment Hits by Combining Multi‐Step Array Synthesis With HT Crystallography
    Harold Grosjean, A. Aimon, Storm Hassell‐Hart, Warren Athol Thompson, L. Koekemoer, James M. Bennett, Anthony R Bradley, Cameron Anderson, Conor Francis Wild, William J. Bradshaw et al. · 2025 · Angewandte Chemie International Edition
  60. Potent and selective SETDB1 covalent negative allosteric modulator reduces methyltransferase activity in cells
    Mélanie Uguen, Devan J. Shell, Madhushika Silva, Yu Deng, Fengling Li, Magdalena M. Szewczyk, Ka Yang, Yani Zhao, Michael A. Stashko, Jacqueline L. Norris-Drouin et al. · 2025 · Nature Communications
  61. Toward routine utilisation of native mass spectrometry as an enabler of contemporary drug development
    Louise M. Sternicki, Sally‐Ann Poulsen · 2025 · RSC Medicinal Chemistry
  62. New Cysteine Covalent Modification Strategies Enable Advancement of Proteome‐wide Selectivity of Kinase Modulators
    Ivy A. Guan, Kayla Williams, Jolyn Pan, Xuyu Liu · 2021 · Asian Journal of Organic Chemistry
  63. Maximizing the integration of virtual and experimental screening in hit discovery
    Dávid Bajusz, György Miklós Keserű · 2022 · Expert Opinion on Drug Discovery
  64. α‐Lactam Electrophiles for Covalent Chemical Biology**
    Alejandro Mahía, Anders E. Kiib, Marija Nišavić, Esben B. Svenningsen, Johan Palmfeldt, Thomas Bjørnskov Poulsen · 2023 · Angewandte Chemie International Edition
  65. Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories
    Anthony Feral, Anthony R. Martin, Alexandre Desfoux, Muriel Amblard, Lubomir Vezenkov · 2023 · Amino Acids
  66. Fragment-Based Discovery of Irreversible Covalent Inhibitors of Cysteine Proteases Using Chlorofluoroacetamide Library
    Chizuru Miura, Naoya Shindo, Kei Okamoto, Keiko Kuwata, Akio Ojida · 2020 · Chemical and Pharmaceutical Bulletin
  67. Covalent fragment-based ligand screening approaches for identification of novel ubiquitin proteasome system modulators
    Elisabeth M. Rothweiler, Paul E. Brennan, K. Huber · 2022 · Biological Chemistry
  68. Identification of covalent inhibitors of Staphylococcus aureus serine hydrolases important for virulence and biofilm formation
    Tulsi Upadhyay, Emily C. Woods, Stephen Dela Ahator, Kjersti Julin, Franco F. Faucher, Md Jalal Uddin, Marijn J. Hollander, Nichole J. Pedowitz, Daniel Abegg, Isabella Hammond et al. · 2025 · Nature Communications
  69. Tumour-specific STING agonist synthesis via a two-component prodrug system
    Nai‐Shu Hsu, Cong Tang, Raquel Valente Mendes, Carlos Labão‐Almeida, C.V. dos Reis, Ana Raquel Coelho, Marta C. Marques, Mar Cabeza-Cabrerizo, Roman Misteli, Timothy P. C. Rooney et al. · 2025 · Nature Chemistry
  70. Developments and challenges in hit progression within fragment-based drug discovery
    Harold Grosjean, Philip Charles Biggin · 2026 · Nature Communications
  71. Azapeptide activity-based probes for the SARS-CoV-2 main protease enable visualization of inhibition in infected cells
    Roeland Vanhoutte, Marta Barniol‐Xicota, Winston Chiu, Laura Vangeel, Dirk Jochmans, Steven De Jonghe, Hadeer Zidane, Haim Michael Barr, Nir London, Johan H. Neyts et al. · 2023 · Chemical Science
  72. Reactive Docking: A Computational Method for High-Throughput Virtual Screenings of Reactive Species
    Giulia Bianco, Matthew Holcomb, Diogo Santos‐Martins, Andreas F. Tillack, Althea Hansel-Harris, Stefano Forli · 2023 · Journal of Chemical Information and Modeling
  73. Advanced technologies for screening and identifying covalent inhibitors
    Yaolin Guo, Shuai Wen, Aiping Tong, Yuxi Wang · 2024 · TrAC Trends in Analytical Chemistry
  74. Exploring 2-Sulfonylpyrimidine Warheads as Acrylamide Surrogates for Targeted Covalent Inhibition: A BTK Story
    Ruxandra Moraru, Beatriz Valle‐Argos, Annabel R. Minton, Lara E. Buermann, Suyin Pan, Thomas E. Wales, Raji E. Joseph, Amy Hamilton Andreotti, Jonathan C. Strefford, Graham Packham et al. · 2024 · Journal of Medicinal Chemistry
  75. Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases
    Dakshinamurthy Sivakumar, Matthias Stein · 2021 · Biomolecules
  76. Covalent Ligand Electrophiles Are Differentially Activated by Proximity Effects Which Govern Latent Protein Reactivity
    Tomas V. Frankovich, Harrison M. McCann, Kyle S. Hoffman, Anthony F. Rullo · 2025 · ACS Central Science
  77. Targeting a key protein-protein interaction surface on mitogen-activated protein kinases by a precision-guided warhead scaffold
    Ádám Levente Póti, Dániel Bálint, Anita Alexa, Péter Sok, Kristóf Ozsváth, Krisztián Albert, Gábor Turczel, Sarolt Magyari, Orsolya Ember, Kinga Papp et al. · 2024 · Nature Communications
  78. Diversity oriented clicking for modular synthesis
    Zifei Wang, Joshua A. Homer, Elias K. Zegeye, Lucas Dada, Dennis W. Wolan, Seiya Kitamura, John E. Moses · 2025 · Nature Reviews Methods Primers
  79. Best Practices for Design and Characterization of Covalent Chemical Probes
    Ronen Gabizon, Efrat Resnick, Nir London · 2020 · Royal Society of Chemistry eBooks
  80. Mercapto-pyrimidines are reversible covalent inhibitors of the papain-like protease (PLpro) and inhibit SARS-CoV-2 (SCoV-2) replication
    Teena Bajaj, Eddie Wehri, Rahul K. Suryawanshi, Elizabeth King, Kundansingh A. Pardeshi, Kamyar Behrouzi, Zahra Khodabakhshi, Ursula Schulze‐Gahmen, G. Renuka Kumar, Mohammad R. K. Mofrad et al. · 2023 · RSC Advances
  81. Identification of Highly Selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors by a Covalent Fragment-Based Approach
    Fubao Huang, Hangchen Hu, Kai Wang, Chengyuan Peng, Wenwei Xu, Yu Zhang, Jing Gao, Yishen Liu, Hu Zhou, Ruimin Huang et al. · 2020 · Journal of Medicinal Chemistry
  82. Contribution of Noncovalent Recognition and Reactivity to the Optimization of Covalent Inhibitors: A Case Study on KRasG12C
    Nikolett Péczka, Ivan Ranđelović, Zoltán Orgován, Noémi Csorba, Attila Egyed, László Petri, Péter Ábrányi‐Balogh, Márton Gadanecz, András Perczel, József Tóvári et al. · 2024 · ACS Chemical Biology
  83. Mapping protein binding sites by photoreactive fragment pharmacophores
    Péter Ábrányi‐Balogh, Dávid Bajusz, Zoltán Orgován, Aaron B. Keeley, László Petri, Nikolett Péczka, Tibor Viktor Szalai, Gyula Pálfy, Márton Gadanecz, Emma K. Grant et al. · 2024 · Communications Chemistry
  84. Emerging opportunities for intact and native protein analysis using chemical proteomics
    Alexis N. Edwards, Ku‐Lung Hsu · 2024 · Analytica Chimica Acta
  85. Size-Dependent Target Engagement of Covalent Probes
    László Petri, Ronen Gabizon, György G. Ferenczy, Nikolett Péczka, Attila Egyed, Péter Ábrányi‐Balogh, Tamás Takács, György Miklós Keserű · 2025 · Journal of Medicinal Chemistry
  86. Covalent fragment mapping of KRasG12C revealed novel chemotypes with in vivo potency
    Zoltán Orgován, Nikolett Péczka, László Petri, Péter Ábrányi‐Balogh, Ivan Ranđelović, Szilárd Tóth, Gergely Szakács, Kinga Nyíri, Beáta G. Vértessy, Gyula Pálfy et al. · 2023 · European Journal of Medicinal Chemistry
  87. Solid Phase Synthesis of Fluorosulfate Containing Macrocycles for Chemoproteomic Workflows
    Franco F. Faucher, Daniel Abegg, Phillip Ipock, Alexander Adibekian, Scott Lovell, Matthew S. Bogyo · 2023 · Israel Journal of Chemistry
  88. A covalent inhibitor targeting the papain-like protease from SARS-CoV-2 inhibits viral replication
    Hesong Han, Albert Vallejo Gracia, Joachim Justad Røise, Lydia Boike, Kristoffer E. Leon, Ursula Schulze‐Gahmen, Michael R. Stentzel, Teena Bajaj, Dake Chen, I-Che Li et al. · 2023 · RSC Advances
  89. An electrophilic fragment screening for the development of small molecules targeting caspase-2
    Matthew E. Cuellar, Mu Yang, Karavadhi Surendra, Yaqin Zhang, Hu Zhu, Hongmao Sun, Min Shen, Matthew D. Hall, Samarjit Patnaik, Karen H. Ashe et al. · 2023 · European Journal of Medicinal Chemistry
  90. Cellular Validation of a Chemically Improved Inhibitor Identifies Monoubiquitination on OTUB2
    Jin Gan, Jelle de Vries, Jimmy J.L.L. Akkermans, Yassene Mohammed, Rayman T.N. Tjokrodirijo, Arnoud H. de Ru, Robbert Q. Kim, David A. Vargas, Vito Pol, Rudi Fasan et al. · 2023 · ACS Chemical Biology
  91. Covalent drugs based on small molecules and peptides for disease theranostics
    Ying-Jin Zhang, Jian‐Xiao Liang, Yinsheng Xu, Yixuan Liu, Ying-Ying Cui, Zeng‐Ying Qiao, Hao Wang · 2023 · Biomaterials Science
  92. Covalent fragment libraries in drug discovery—Design, synthesis, and screening methods
    Brad J. W. Hocking, Alan Armstrong, David J. Mann · 2023 · Progress in medicinal chemistry
  93. Pervasive aggregation and depletion of host and viral proteins in response to cysteine-reactive electrophilic compounds
    Ashley R. Julio, Flowreen Shikwana, Cindy C. Truong, Nikolas R. Burton, Emil R. Dominguez, Alexandra C. Turmon, Jian Xin Cao, Keriann M. Backus · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  94. Antibiotic target discovery by integrated phenotypic and activity-based profiling of electrophilic fragments
    Yizhen Jin, Sadhan Jana, Mikail E. Abbasov, Hening Lin · 2025 · Cell chemical biology
  95. COOKIE-Pro: covalent inhibitor binding kinetics profiling on the proteome scale
    Hanfeng Lin, Bin Yang, Lang Ding, Yen‐Yu Yang, Matthew Valle Holt, Sung Yun Jung, Bing Zhang, Meng Carla Wang, Jin Wang · 2025 · Nature Communications
  96. Activity‐Based Protein Profiling Identifies Protein Disulfide‐Isomerases as Target Proteins of the Volatile Salinilactones
    Karoline Jerye, Helko Lüken, Anika Steffen, Christian Schlawis, Lothar Jänsch, Stefan Schulz, Mark Brönstrup · 2024 · Advanced Science
  97. Covalent Fragment Screening Identifies Rgl2 RalGEF Cysteine for Targeted Covalent Inhibition of Ral GTPase Activation
    Khuchtumur Bum‐Erdene, Mona K. Ghozayel, David Daqiang Xu, Samy O. Meroueh · 2022 · ChemMedChem
  98. A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands
    Emma K. Grant, David J. Fallon, Michael M. Hann, Ken G. M. Fantom, Chad J. Quinn, Francesca Zappacosta, Roland S. Annan, Chun‐wa Chung, Paul Bamborough, David P. Dixon et al. · 2020 · Angewandte Chemie
  99. Chemical proteomic identification of functional cysteines with atypical electrophile reactivities
    Kevin M. Litwin, Vincent M. Crowley, Radu M. Suciu, Dale L. Boger, Benjamin F. Cravatt · 2021 · Tetrahedron Letters
  100. Sulfopin, a selective covalent inhibitor of Pin1, blocks Myc-driven tumor initiation and growth in vivo
    Christian Dubiella, Benika J. Pinch, Daniel Zaidman, Theresa D. Manz, Evon Poon, Shuning He, Efrat Resnick, Ellen M. Langer, Colin J. Daniel, Hyuk‐Soo Seo et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)